Skip to main content
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. — Investor Relations & Filings

Ticker · ERNA ISIN · US6294106066 US Manufacturing
Open in API
Filings indexed 1,027 across all filing types
Latest filing 2024-01-03 Director's Dealing
Country US United States of America
Listing US ERNA

About Ernexa Therapeutics Inc.

https://www.ernexatx.com/

Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2024-01-03 English
Director's Dealing 2024
Director's Dealing
2024-01-03 English
SC 13D/A
Major Shareholding Notification
2023-12-22 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 14, 2023, for Eterna Therapeutics Inc. It includes detailed disclosures about a private placement of convertible notes and warrants, describing the terms of the securities, registration rights, and related agreements. Additionally, it announces a change in senior management, specifically the resignation of the CEO and appointment of a new CEO, with detailed information about the new CEO's background and employment agreement. The Form 8-K is a current report used to disclose material events such as financing transactions and management changes. The content fits the category of Capital/Financing Update due to the private placement details and Board/Management Information due to the CEO change. However, since the document contains both but the financing update is the primary and first detailed item, and the management change is a secondary item, the best classification is Capital/Financing Update (CAP). The document is not an annual or quarterly report, nor an earnings release, nor a proxy or voting result. It is a regulatory filing but more specifically a capital/financing update with management change information included. Confidence is high given the detailed financing terms and management appointment disclosures in a Form 8-K.
2023-12-20 English
SC 13G
Major Shareholding Notification
2023-12-20 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-12-20 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.